Autopsy report · NCT04044560
Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant
Cause of deathSlow enrollment, also funding or business
“Slow enrolment, loss of funding”
Life of this trial
- Registered 1 year 1 month before it started.
- Ran for about 1 year 5 months before it stopped.
- 8 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- University of British Columbia
- Sponsor type
- University, hospital or other
- Conditions
- B-cell Adult Acute Lymphoblastic Leukemia; Stem Cell Leukemia; Minimal Residual Disease
- Interventions
- blinatumomab
- Participants
- 8
- Sites
- 3
- Countries
- Canada
Trials that died the same way
- Clinical Trial of Nebulized Hypertonic Saline to Attenuate Post-Traumatic Acute Lung Injury
“low enrollment and loss of funding” - Quantitative Imaging Biomarkers of Treatment Response in Osteosarcoma and Ewing Sarcoma
“Slow accrual and lack of funding” - Evaluate The Effectiveness Of Fospropofol (Lusedra®) For Induction Of Anesthesia
“Loss of funding before enrollment.” - Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcomes in Older Patients Undergoing CAR-T Therapy for Relapsed or Refractory Multiple Myeloma
“Limited funding, slow accrual” - Effect of Establishing Functional Residual Capacity During Newborn Resuscitation on Oxygenation
“Slow enrolment”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.